Your browser doesn't support javascript.
loading
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Fowler, Nathan H; Davis, R Eric; Rawal, Seema; Nastoupil, Loretta; Hagemeister, Fredrick B; McLaughlin, Peter; Kwak, Larry W; Romaguera, Jorge E; Fanale, Michelle A; Fayad, Luis E; Westin, Jason R; Shah, Jatin; Orlowski, Robert Z; Wang, Michael; Turturro, Francesco; Oki, Yasuhiro; Claret, Linda C; Feng, Lei; Baladandayuthapani, Veerabhadran; Muzzafar, Tariq; Tsai, Kenneth Y; Samaniego, Felipe; Neelapu, Sattva S.
Afiliação
  • Fowler NH; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: nfowler@mdanderson.org.
  • Davis RE; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Rawal S; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nastoupil L; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hagemeister FB; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • McLaughlin P; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kwak LW; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Center for Cancer Immunology Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Romaguera JE; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fanale MA; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fayad LE; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Westin JR; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Shah J; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Orlowski RZ; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang M; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Turturro F; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Oki Y; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Claret LC; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Feng L; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Baladandayuthapani V; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Muzzafar T; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tsai KY; Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Samaniego F; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Neelapu SS; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Center for Cancer Immunology Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lancet Oncol ; 15(12): 1311-8, 2014 Nov.
Article em En | MEDLINE | ID: mdl-25439689
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Talidomida / Linfoma não Hodgkin / Linfoma Folicular / Anticorpos Monoclonais Murinos / Recidiva Local de Neoplasia Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Talidomida / Linfoma não Hodgkin / Linfoma Folicular / Anticorpos Monoclonais Murinos / Recidiva Local de Neoplasia Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2014 Tipo de documento: Article